Retatrutide vs Every Weight Loss Drug: Complete Ranking
Retatrutide sits atop the weight loss drug hierarchy with 24.2% average weight loss in Phase 2 trials (Jastreboff et al., NEJM 2023). But how does it compare to every other weight loss medication ever approved or in development? This complete ranking places retatrutide in context against every drug that has ever claimed to treat obesity — from the most effective to the least. The results make clear how far the field has come in just a few years.
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Cross-trial comparisons have inherent limitations due to differences in study design, patient populations, and duration. Always consult a qualified healthcare provider.
The Complete Weight Loss Drug Ranking
| Rank | Drug | Avg Weight Loss | Status |
|---|---|---|---|
| 1 | Retatrutide 12mg | 24.2% | Investigational (Phase 3) |
| 2 | Tirzepatide 15mg (Zepbound) | 22.5% | FDA-approved |
| 3 | CagriSema | ~22% | Investigational (Phase 3) |
| 4 | Semaglutide 2.4mg (Wegovy) | ~15% | FDA-approved |
| 5 | Orforglipron | ~14.7% | Investigational (Phase 3) |
| 6 | Survodutide | ~14-19% | Investigational (Phase 3) |
| 7 | Liraglutide 3mg (Saxenda) | ~8% | FDA-approved |
| 8 | Phentermine/topiramate (Qsymia) | ~8-10% | FDA-approved |
| 9 | Naltrexone/bupropion (Contrave) | ~5-8% | FDA-approved |
| 10 | Phentermine alone | ~5-7% | FDA-approved (short-term) |
| 11 | Orlistat (Xenical/Alli) | ~3-5% | FDA-approved |
| 12 | Metformin (off-label) | ~2-5% | Off-label for weight loss |
Cross-trial comparisons have inherent limitations. Weight loss percentages are approximate averages from pivotal trials.
Three Tiers of Obesity Treatment
The ranking reveals three clear tiers. Tier 1 (20%+ weight loss): Retatrutide, tirzepatide, and CagriSema. These represent the cutting edge — multi-receptor agonists that produce results approaching bariatric surgery. Tier 2 (10-19% weight loss): Semaglutide, orforglipron, and survodutide. Single or dual agonists with solid but less dramatic results. Tier 3 (under 10% weight loss): Older medications (Saxenda, Qsymia, Contrave, phentermine, orlistat) that produce modest results by modern standards.
Why Retatrutide Leads the Pack
Retatrutide's triple mechanism is what places it at the top. No other drug simultaneously reduces caloric intake (GLP-1), improves metabolic efficiency (GIP), and increases energy expenditure (glucagon). Even tirzepatide, the current most effective approved drug, lacks the glucagon component. The glucagon receptor adds approximately 2-5 percentage points of additional weight loss and provides unique benefits for liver fat and body composition.
Important Caveats
Cross-trial comparisons are inherently limited. Different studies use different patient populations, different baseline weights, different durations, and different dietary interventions. The only way to definitively compare two drugs is in a head-to-head randomized trial, which has not been done for most of these comparisons. These rankings should be taken as general guidance, not precise measurements.
Additionally, efficacy is not the only factor that matters. Side effect profiles, administration method (pill vs injection), cost, availability, and individual patient factors all influence treatment selection.
What Is Available Today
Of the top-tier drugs, only tirzepatide is currently FDA-approved. Semaglutide, the Tier 2 leader, is also available and highly effective. Both are accessible through compounding at affordable prices. Trimi offers compounded semaglutide at $99/month and compounded tirzepatide at $125/month — providing access to Tier 1 and Tier 2 medications at a fraction of brand costs. Get started with Trimi today.
Frequently Asked Questions
What is the most effective weight loss drug available today?
Tirzepatide (Zepbound/Mounjaro) at 22.5% average weight loss is the most effective currently FDA-approved weight loss medication. Compounded tirzepatide is available through Trimi at $125/month.
When will retatrutide be available?
Retatrutide is in Phase 3 TRIUMPH trials. FDA approval is projected for late 2027 to 2028 if trials are successful. There is no way to obtain retatrutide legally outside of clinical trials at this time.
Should I wait for retatrutide or start treatment now?
Start treatment now. Tirzepatide and semaglutide are highly effective, available today, and affordable through compounding. You can always transition to retatrutide when it becomes available. Waiting means 1-2 years of untreated obesity.
Are older weight loss drugs worth taking?
With semaglutide available at $99/month and tirzepatide at $125/month through compounding, older drugs like phentermine, Contrave, and orlistat are difficult to justify for most patients. The newer GLP-1 medications are dramatically more effective with better safety profiles.
More on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).